Interview with Patrice Zagamé, CEO, Novartis France
You worked for many years in emerging markets, especially in Latin America, but also in neighbor countries such as Spain. How these previous experiences in very different markets can now…
AREVA Med is an AREVA subsidiary created in 2009 to develop innovative therapies to fight cancer.
Based on an R&D program started in 2005, AREVA Med has been able to develop new processes for producing high-purity lead-212 (212Pb), a rare radioactive isotope. 212Pb is currently at the heart of promising research projects in nuclear medicine to develop new treatments against cancer.
The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells without damaging nearby healthy cells.
Contact
Tel.: + 1 (301) 841-1673
email: alison.tise@areva.com
Web: arevamed.areva.com
You worked for many years in emerging markets, especially in Latin America, but also in neighbor countries such as Spain. How these previous experiences in very different markets can now…
In the wake of the most recent CSIS meeting, LFB and Sanofi-Aventis announced the intention to collaborate in bioproduction. What are the terms to this agreement and what are the…
We have had the chance to interview a number of Teva’s subsidiaries in Europe, and witnessed how each of them has dealt with the strong transformations that the group has…
Historically, UCB Pharma had a much more ‘traditional’ approach to the industry with a broader scope of operations. Recently, the company reoriented in the direction of biopharmaceuticals by moving away…
Novo Nordisk just celebrated 50 years in France; what have been some of the more recent events that have marked the affiliate’s time here? If you look from the perspective…
Baxter is approaching 40 years in France, what have been the major milestones of the group during this period and what is the importance of France to the group? During…
Sandoz has set important trends in the pharmaceutical market, first by creating a leading global generics business under the umbrella of parent company Novartis, and secondly by investing heavily in…
How would you define the Institut Pasteur’s relationship with the pharmaceutical industry and how it has evolved in recent years? Since its foundation 120 years ago, the Institut Pasteur has…
Nordic Pharma has been established in the French market since 2002 as one of its first steps towards internationalization. What have been the main milestones and achievements of Nordic in…
In only four years Celgene has introduced a number of important products in the French market and is now seen as a preeminent biopharmaceutical company in hematology. As the head…
Octapharma was founded in 1983 and entered decisively in the French market in 1999, when it acquired a plasma facility in Lingolsheim, Alsace. Since then, what have been the main…
As the market leader in the French pre-wholesale market, Depolado had a quite impressive market share growth in the previous 3 years, now being responsible for a quarter of the…
See our Cookie Privacy Policy Here
